Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate

British Journal of Cancer

Volumn 106, Issue 8, 2012, Pages 1464-1465

  Dickinson, P D ^a   Peel, D N Y ^b   Sundar, S ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; PROSTATE SPECIFIC ANTIGEN;

AGED; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG FATALITY; GLEASON SCORE; HEART INFARCTION; HUMAN; LETTER; LOW DRUG DOSE; MALE; METASTASIS; METRONOMIC DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTATE CARCINOMA; RETROSPECTIVE STUDY; STUDENT T TEST;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; MALE; METHOTREXATE; NEOPLASMS; PYRAZOLES; SULFONAMIDES;

EID: 84859638799     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.78     Document Type: Letter

References (4)

1. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Vollmer R, Wilding G (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the PSA working group. J Clin Oncol 17: 3461-3467 (Pubitemid 29517916)
2. Glode M, Barqawi A, Crawford E, Kerbel R (2003) Metronomic therapy with cyclophosphamide and dexamethasone for prostate cancer. Cancer 99: 1643-1648 (Pubitemid 37238620)
3. Khan OA, Blann AD, Payne MJ, Middleton MR, Protheroe AS, Talbot DC, Taylor M, Kirichek O, Han C, Patil M, Harris AL (2011) Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer. Br J Cancer 104: 1822-1827
4. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M, Prostate Cancer Clinical Trials Working Group (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol 26: 1148-1159